Track topics on Twitter Track topics that are important to you
Roche this morning agreed to acquire the part of Foundation Medicine it didn’t already own, another big vote of confidence in the broad tumor profiling panels that have struggled to gain traction but have picked up momentum recently. Roche will pay $137 per share, or $2.4 billion, for the remaining stock of Foundation (NASDAQ: FMI), […]
Original Article: In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation MedicineNEXT ARTICLE
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...